Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 164.7% in December

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 100,600 shares, an increase of 164.7% from the December 15th total of 38,010 shares. Based on an average trading volume of 687,336 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 687,336 shares, the days-to-cover ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS BAYRY opened at $12.09 on Thursday. Bayer Aktiengesellschaft has a 1 year low of $5.29 and a 1 year high of $12.14. The firm has a market capitalization of $47.51 billion, a price-to-earnings ratio of -134.32, a P/E/G ratio of 5.60 and a beta of 0.66. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The firm’s 50 day simple moving average is $9.79 and its 200 day simple moving average is $8.63.

Wall Street Analyst Weigh In

BAYRY has been the topic of a number of analyst reports. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Zacks Research cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Finally, Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.